论文部分内容阅读
目的探讨血清α1-抗胰蛋白酶(α1-AT),胆碱酯酶(CHE)和甲胎蛋白(AFP)检测在肝癌诊断中的临床意义。方法随机筛选肝癌患者、良性肝病患者及健康体检者各45例,分别检测其血清α1-AT,CHE及AFP含量,统计分析各组间结果差异,并比较三种指标单独或联合检测对肝癌诊断的敏感性和特异性。结果血清α1-AT,CHE及AFP含量在肝癌患者组明显高于良性肝病患者组及健康体检组,差异有统计学意义(P<0.05);对肝癌的诊断方面,单项检测αl-AT、CHE及AFP的敏感性分别为87%、89%和82%,特异性分别为74%、80%和90%;三项联合检测的敏感性为93%,特异性为70%。结论三项联合检测提高了肝癌诊断的敏感性,有利于肝癌的早期诊断,降低了对肝癌的漏诊。
Objective To investigate the clinical significance of serum α1-AT, CHE and AFP in the diagnosis of liver cancer. Methods Forty-five patients with hepatocellular carcinoma (HCC), benign liver disease (HCC) and 45 healthy individuals were randomly selected and their serum levels of α1-AT, CHE and AFP were detected. The differences among the groups were statistically analyzed. Sensitivity and specificity. Results Serum levels of α1-AT, CHE and AFP were significantly higher in HCC patients than those in benign liver disease patients and healthy controls (P <0.05). For the diagnosis of HCC, And AFP were 87%, 89% and 82% respectively, and the specificity was 74%, 80% and 90% respectively. The sensitivity and specificity of the three combined tests were 93% and 70% respectively. Conclusions The three combined tests can increase the sensitivity of HCC diagnosis, facilitate the early diagnosis of HCC and reduce the missed diagnosis of HCC.